In a recent development, a Delaware federal judge has ruled in favor of Natera Inc., maintaining the validity of two of their patents related to cancer testing products. The court dismissed arguments put forward by ArcherDX, a competitor, that suggested Natera had delayed in filing the patents and in launching its lawsuit for infringement against ArcherDX. The full details of the litigation and its implications are reported on in an article by Hailey Konnath on Law360. You can read it here.
This court decision follows a $19M verdict against ArcherDX. The ruling further solidifies Natera’s standing in the field of cancer diagnostic testing, and reinforces the notion that innovators in this field will robustly defend intellectual property linked with critical advancements in medical technology.